Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Nakamura, Hiroki; Sakai, Hiroki; Kimura, Hiroyuki; Miyazawa, Tomoki; Marushima, Hideki; Saji, Hisashi

doi:10.5761/atcs.oa.17-00020

Cited by 22 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molinier et al [24] estimated 5year survival in non-small-cell lung cancer patients and found that smoking level at diagnosis was an independent negative prognostic factor in LUSC patients. Nakamura et al [25] performed the multivariate analysis to find that smoking in LUSC was associated with recurrence-free survival. Although without distinguishing histological type, a cohort claimed that recent quitting could decrease the risk of death among patients with lung cancer (HR, 0.90; 95% CI 0.81-0.99) [11].…”

Section: Discussionmentioning

confidence: 99%

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi‐omics data

2020

View full text Add to dashboard Cite

Few studies have examined the association between smoking status (including former smokers) at diagnosis and overall survival among cancer patients. We aimed to assess the benefits of quitting smoking on cancer prognosis in cohorts of cancer patient smokers obtained from the Cancer Genome Atlas (TCGA) database. Hazard ratios (HR) were calculated to evaluate smoking behavior at cancer diagnosis (reformed smokers vs. current smokers) in association with overall survival using multivariate‐adjusted Cox regressions analysis. According to our analyses, quitting smoking was the independent protective factor for overall survival in lung squamous cell carcinoma (LUSC) (HR = 0.67, 95% CI = 0.48–0.94). Comprehensive analysis of multicomponent data across reformed and current smokers identified a total of 85 differential expressed genes (DEGs) affected by different modes of genetic and epigenetic regulation, potentially representing cancer drivers in smokers. Moreover, we provided a smoking‐associated gene expression signature, which could evaluate the true effect on prognosis with high power (HR = 1.70, 95% CI = 1.19–2.43, AUC = 0.65, 0.67, and 0.70 for 2‐, 3‐, and 5‐year survival, respectively). This signature was also applicable in other smoking‐related cancers, including bladder urothelial carcinoma (HR = 1.70, 95% CI = 1.01–2.88), cervical carcinoma (HR = 5.69, 95% CI = 1.37–23.69), head and neck squamous cell carcinoma (HR = 1.97, 95% CI = 1.41–2.76), lung adenocarcinoma (HR = 1.73, 95% CI = 1.16–2.57), and pancreatic adenocarcinoma (HR = 4.28, 95% CI = 1.47–12.47). In conclusion, this study demonstrates that quitting smoking at diagnosis decreases risk of death in cancer patients. We also provide a smoking‐associated gene expression signature to evaluate the effect of smoking on survival. Lastly, we suggest that smoking cessation could comprise a part of cancer treatment to improve survival rates of cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi‐omics data

2020

View full text Add to dashboard Cite

show abstract

“…Conversely, no difference was found when we analysed DFS, but, among those who had a recurrence, those with squamous cell carcinoma had a significantly worse survival. A worse survival with a concomitant, similar DFS for patients with squamous cell carcinoma compared to adenocarcinoma has been reported by other authors [21][22][23], who concluded that the difference in the mortality rate might be associated with noncancer-related causes; nevertheless, Fukui et al found more deaths among patients with a recurrent squamous cell carcinoma than among those with adenocarcinoma. They, therefore, proposed a reclassification of T1a-bN0 and T2N0 squamous cell NSCLC as Stage IIA.…”

Section: Discussionmentioning

confidence: 72%

N2 lung cancer is not all the same: an analysis of different prognostic groups†

Bertoglio

Ricciardi

Alì

et al. 2018

Interactive CardioVascular and Thoracic Surgery

View full text Add to dashboard Cite

OBJECTIVES:The International Association for the Study of Lung Cancer (IASLC) recently proposed a change in the staging system for N2, based on the metastatic station number: N2a1 (a single metastatic station with no hilar involvement), N2a2 (a single metastatic station with hilar involvement) and N2b (multiple metastatic stations). The aim of our study was to validate the IASLC proposal in a cohort of patients with pathological N2 disease. METHODS:All patients with pathological T1-T2 N2 non-small-cell lung cancer who were operated on between 2006 and 2010 in our department were enrolled. The patients had lobectomy, bilobectomy or pneumonectomy without induction therapy; patients with any type of extended resection were excluded. All patients had adjuvant treatment. The impact of the new IASLC proposal on the overall and disease-free survival rates was then analysed. RESULTS:Ninety-three patients were selected. The median follow-up period and overall survival time were 92 and 28.8 months, respectively. According to the new IASLC proposal, we observed 22 cases of N2a1, 54 N2a2 and 17 N2b. Patients with N2a1 had a significantly better overall survival than those with N2a2 and N2b (P = 0.041); the difference between N2a2 and N2b was not significant (P = 0.19). Patients with N2a1 squamous cell carcinoma had a significantly better overall survival than those with other histological diagnoses (P = 0.046). The disease-free interval was longer in patients with N2a1 than those in other groups (P = 0.021).CONCLUSIONS: Our experience partially validates the IASLC proposal; the introduction of quantitative criteria for N staging might improve stratification of patients and the assignment to the correct therapeutic path.

show abstract

“…Molinier et al (27) estimated five-year survival in non-small-cell lung cancer patients and found that smoking level at diagnosis was an independent negative prognostic factor in LUSC patients. Nakamura et al (28) performed the multivariate analysis to find that smoking in LUSC was associated with recurrence-free survival. Although without distinguishing histological type, a cohort claimed that recent quitting could decrease the risk of death among patients with lung cancer (HR, 0.90; 95% CI 0.81-0.99) (11).…”

Section: Discussionmentioning

confidence: 99%

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data

Yang¹,

Liu²,

Liang³

2020

Preprint

View full text Add to dashboard Cite

Background: Few studies have examined the association between smoking cessation at the time of diagnosis and overall survival among cancer patients. We aimed to assess the benefits of quitting smoking on prognosis.Methods: We obtained cohorts of smoking-related cancer patients from the Cancer Genome Atlas (TCGA) database. Hazard ratios (HR) with 95% confidence intervals (CIs) were calculated to evaluate smoking behavior at cancer diagnosis (reformed smokers vs. current smokers) in association with overall survival using age and multivariate-adjusted Cox regressions analysis. Comprehensive analysis of multi-component data was carried out to determine the genetic and epigenetic landscape differences and their effects on the differential expression genes (DEGs) between reformed smokers and current smokers. The smoking signature was constructed using univariate Cox regression and LASSO-Cox regression model.Results: According to the multivariate-adjusted Cox regressions analysis, quitting smoking was the independent protective factor for overall survival in lung squamous cell carcinoma (LUSC) (HR=0.67, 95%CI=0.48-0.94). A total of 85 key DEGs were found to be affected by different modes of genetic and epigenetic regulation, which might represent key drivers in smokers. At last, we provided the smoking signature which could predict prognosis with high power (HR=1.70, 95% CI=1.19-2.43, AUC= 0.65, 0.67 and 0.70 for 2, 3 and 5-year survival, respectively). The smoking signature was also applicable in other smoking-related cancers, including bladder urothelial carcinoma (HR=1.70, 95% CI=1.01-2.88), cervical carcinoma (HR=5.69, 95% CI=1.37-23.69), head and neck squamous cell carcinoma (HR=1.97, 95% CI=1.41-2.76), lung adenocarcinoma (HR=1.73, 95% CI=1.16-2.57), and pancreatic adenocarcinoma (HR=4.28, 95% CI=1.47-12.47).Conclusions: The present study demonstrated that quitting smoking at diagnosis decreased risk of death in cancer patients. We also provided the smoking signature to evaluate the true effect of smoking, suggesting that smoking cessation could be a part of cancer treatment to improve the survival rate of cancer patients.

show abstract

Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma

Cited by 22 publications

References 30 publications

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi‐omics data

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi‐omics data

N2 lung cancer is not all the same: an analysis of different prognostic groups†

The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data

Contact Info

Product

Resources

About